These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 23506002)

  • 21. Non-Zinc-Binding Inhibitors of MMP-13: GRID-Based Approaches to Rationalize the Binding Process.
    Di Pizio A; Agamennone M; Tortorella P
    Curr Top Med Chem; 2016; 16(4):449-59. PubMed ID: 26268339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gelatinase inhibitors: a patent review (2011-2017).
    Li X
    Expert Opin Ther Pat; 2018 Jan; 28(1):31-46. PubMed ID: 29130358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A quantitative structure-activity relationship study on a series of selective non-zinc binding inhibitors of MMP13.
    Singh P
    Med Chem; 2014 Mar; 10(2):174-88. PubMed ID: 23627272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trivalent metal ions based on inorganic compounds with in vitro inhibitory activity of matrix metalloproteinase 13.
    Wen H; Qin Y; Zhong W; Li C; Liu X; Shen Y
    Enzyme Microb Technol; 2016 Oct; 92():9-17. PubMed ID: 27542739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel matrix metalloproteinase inhibitors: an updated patent review (2014 - 2020).
    Lenci E; Cosottini L; Trabocchi A
    Expert Opin Ther Pat; 2021 Jun; 31(6):509-523. PubMed ID: 33487088
    [No Abstract]   [Full Text] [Related]  

  • 26. Benzisoxazole analogs as glycogen synthase activators, a patent evaluation (WO2011057956).
    Uto Y
    Expert Opin Ther Pat; 2012 Jun; 22(6):701-7. PubMed ID: 22519818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydantoin based inhibitors of MMP13--discovery of AZD6605.
    De Savi C; Waterson D; Pape A; Lamont S; Hadley E; Mills M; Page KM; Bowyer J; Maciewicz RA
    Bioorg Med Chem Lett; 2013 Aug; 23(16):4705-12. PubMed ID: 23810497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of WO2012037132 - a novel scaffold for selective JAK1 inhibition.
    Norman P
    Expert Opin Ther Pat; 2012 Sep; 22(9):1105-9. PubMed ID: 22812580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study.
    Fuerst R; Yong Choi J; Knapinska AM; Smith L; Cameron MD; Ruiz C; Fields GB; Roush WR
    Bioorg Med Chem; 2018 Oct; 26(18):4984-4995. PubMed ID: 30249495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-Lipoxygenase inhibitors: a patent evaluation (WO2011161615).
    Buscató El; Proschak E
    Expert Opin Ther Pat; 2012 Jul; 22(7):843-6. PubMed ID: 22697185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory effects of caspase inhibitors on the activity of matrix metalloproteinase-2.
    Castro MM; Fuah J; Ali M; Sung M; Schulz J; Kondo MY; Fan X; Holt A; Schulz R
    Biochem Pharmacol; 2013 Aug; 86(4):469-75. PubMed ID: 23774623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 2-Amino-4-arylthiazole compounds as TRPA1 antagonists (WO 2012085662): a patent evaluation.
    De Petrocellis L; Schiano Moriello A
    Expert Opin Ther Pat; 2013 Jan; 23(1):119-47. PubMed ID: 23126422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases.
    Magrioti V; Kokotos G
    Expert Opin Ther Pat; 2010 Jan; 20(1):1-18. PubMed ID: 20021282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aryl amide derivatives of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives useful as ASK1 inhibitors, an evaluation of WO2012080735.
    Norman P
    Expert Opin Ther Pat; 2012 Dec; 22(12):1479-83. PubMed ID: 22917158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variations on brain microglial gene expression of MMPs, RECK, and TIMPs in inflammatory and non-inflammatory diseases in dogs.
    Stein VM; Puff C; Genini S; Contioso VB; Baumgärtner W; Tipold A
    Vet Immunol Immunopathol; 2011 Nov; 144(1-2):17-26. PubMed ID: 21802747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MMP inhibition by barbiturate homodimers.
    Wang J; Radomski MW; Medina C; Gilmer JF
    Bioorg Med Chem Lett; 2013 Jan; 23(2):444-7. PubMed ID: 23246356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategic targeting of multiple water-mediated interactions: a concise and rational structure-based design approach to potent and selective MMP-13 inhibitors.
    Fischer T; Riedl R
    ChemMedChem; 2013 Sep; 8(9):1457-61, 1572. PubMed ID: 23894097
    [No Abstract]   [Full Text] [Related]  

  • 39. CCAAT/enhancer binding protein beta mediates expression of matrix metalloproteinase 13 in human articular chondrocytes in inflammatory arthritis.
    Hayashida M; Okazaki K; Fukushi J; Sakamoto A; Iwamoto Y
    Arthritis Rheum; 2009 Mar; 60(3):708-16. PubMed ID: 19248099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases.
    Leban J; Vitt D
    Arzneimittelforschung; 2011; 61(1):66-72. PubMed ID: 21355448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.